$SRZN News

Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million

Top Biotech Stock: Guggenheim Names Surrozen as Best Pick

Surrozen secures FDA clearance for SZN-8141 clinical trial

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54

Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy

Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

Surrozen Submits IND Application To FDA Seeking To Evaluate SZN-8141, Bifunctional Wnt Agonist And Vascular Endothelial Growth Factor Antagonist Antibody, For Treatment Of Diabetic Macular Edema

Surrozen to Present at Upcoming Healthcare Investor Conferences

HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $44 Price Target

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright

We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate

Surrozen to Present at Upcoming Healthcare Investor Conference

HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $44

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TD Cowen Initiates Coverage On Surrozen with Buy Rating

HC Wainwright & Co. Reiterates Buy on Surrozen, Raises Price Target to $36